

TB Saracen Global Income and Growth Fund

January 2019

SARACEN
share success




Fund Overview

- Objective: to provide a degree of income to investors with the aim of building capital through investing in a portfolio of primarily global equities.
- Focus: on identifying leading global businesses with lower risk and share valuations that underestimate their prospects.
- Research: we conduct intensive proprietary research focusing on businesses' long-term earnings potential.
- Risk: we model a 'worst-case' scenario into our share valuation methodology and abide by strict sector limits.
- Process: Disciplined, structured and repeatable.
- Conviction Portfolio: high active share and highly differentiated.
- Both fund managers have significant personal investments in the fund.

Performance Chart*

Performance since launch (%)

— TB Saracen Global Income & Growth Fund B Acc
— IA Global Equity Income Sector (TR)



*Source: Financial Express, as at 31st January 2019.

Total Return, Bid to Bid, GBP terms. Past performance is not a reliable indicator of future results. The value of your investment and the income derived from it can go down as well as up and you may not get back the money you invested.

Cumulative Performance after all ongoing charges to 31 January 2019

	1 month	6 months	1 year	3 years	5 years	Since launch*
TB SGIG B Acc	+4.4%	-8.4%	-6.9%	+42.2%	+45.9%	+95.5%
Sector Average	+3.8%	-4.8%	-2.0%	+37.2%	+49.2%	+84.1%
Quartile Ranking	2	4	4	2	3	2

Source: Financial Express; *launch date 07 June 2011

Sector: IA Sector (Global Equity Income)

FOR PROFESSIONAL INVESTORS ONLY

Retail investors should consult their financial advisers

FUND DETAILS

(as at 31st January 2019)

Fund size: £118m
Launch date: 07/06/11
Historic yield: 3.5%

No. of holdings: 40
Active share: 93%
Beta: 0.95

Source: Bloomberg as at 31/01/19

Turnover: <20%
Denomination: GBP
Valuation point: 12:00 noon

XD date: 2 Jan
1 July

Pay date: 28/29 Feb
31 Aug

Fund prices:

B Accumulation: 195.00p
B Distribution: 155.36p

Policy is not to charge a dilution levy except in exceptional circumstances.

ACD:

T. Bailey Fund Services Limited

Graham Campbell
Chief Executive Officer

David Keir
Executive Director



Graham Campbell joined Saracen in 2011 from Edinburgh Partners, where he was one of the founding partners and director. He has managed the Fund since launch. Graham has over 30 years of industry experience.

David Keir joined Saracen in 2013 and has managed the Fund since 2014. He has over 18 years of industry experience.




TB Saracen Global Income and Growth Fund

January 2019

SARACEN
share success



Fund Breakdown by Geography



Data as of 31st January 2019, Source: Bloomberg/Saracen Fund Managers

Monthly Commentary

Performance

This month, the total return for TB SGIG was +4.4%, compared to +3.8% for the IA Global Equity Income sector. The fund has delivered a total return of 96% and is ranked second quartile since launch.

FX

Currency movements during January had a significant negative impact on fund performance. Sterling was up 2.8%, 2.5% and 3.8% against the USD, CHF and EUR respectively.

Positives

January marked the beginning of our companies reporting their Q4 numbers and outlook for 2019. Whilst there is increasing evidence of a slowdown in Chinese demand in Q4, our contention remains that many share prices are discounting too pessimistic an outcome. Schlumberger (+20%) bounced strongly after reporting solid numbers and were cautiously optimistic about activity recovering. IBM (+16%) also recovered from their recent lows after posting a good quarter and strong momentum in the business as they enter 2019. Ashmore (+11%) reported inflows in Q4 despite the tougher market conditions. Corning (+9%) had a strong Q4 and issued upbeat 2019 guidance. Many of our shares which had a tough Q4 began to recover. Our holdings in Carnival Corp. (+15%), Evonik (+8%), Heidelberg Cement (+11%) and Johnson Matthey (+11%) all performed strongly.

Negatives

In a strong month for equities, there were few negatives. Our holdings in the Pharmaceutical sector, which performed very strongly in 2018, were subject to profit taking in the market – AstraZeneca (-5%), Merck (-5%) and Pfizer (-6%) all had a soft month. Intel (-1%) reported strong results for 2018 but noted a slowdown in China and gave cautious guidance for Q1.

Portfolio Activity

There were no changes to the portfolio holdings during the month. We took some profits in Ashmore, Rio Tinto and Roche. The proceeds were invested across a group of very lowly rated stocks where we have high conviction, like AIB Group, Carnival Corp, Johnson Matthey and Saint Gobain.

January – Attribution *

Top Contributors	Positive
IBM	+0.56%
Schlumberger	+0.49%
Johnson Matthey	+0.41%
HeidelbergCement	+0.41%
Dow Chemicals	+0.38%
Top Detractors	Negative
Merck	-0.16%
Pfizer	-0.14%
Svenska Handelsbanken	-0.11%
AstraZeneca	-0.08%
Intel	-0.04%

*Source: Bloomberg as at 31/01/19

Fund Breakdown

Top 10 Holdings	
Roche	4.5%
DowDuPont	4.3%
Heidelberg Cement	3.8%
HSBC	3.7%
Johnson Matthey	3.7%
Saint Gobain	3.6%
Evonik	3.6%
IBM	3.6%
Intel	3.5%
Svenska Handelsbanken	3.4%

Sector breakdown	
Financials	19.8%
Industrials	16.5%
Healthcare	15.6%
Basic Materials	14.6%
Technology	11.6%
Oil & Gas	7.5%
Consumer Goods	7.3%
Consumer Services	7.1%
Utilities	0.0%
Cash	0.0%

	ISIN	SEDOL	Bloomberg	EMX	Initial Charge	Annual Charge	Ongoing ** Charge
B Acc Shares	GB00B5B35X02	B5B35X0	SARBACC LN	SARGGIFA	0%	0.75%	0.99%
B Dis Shares	GB00B3XPLG55	B3XPLG5	SARGIGA LN	SARGGIFD	0%	0.75%	0.99%

** Source: T Bailey Fund Services Ltd

To place a deal or for further information contact:

T. Bailey Fund Services Limited (TBFS)
64 St. James's Street
Nottingham
NG1 6FJ

General Enquiries: 0115 988 8200
Dealing Line: 0115 988 8274
E-mail Dealing: clientservices@tbailey.co.uk

(Phone and email deals will only be accepted on completion of initial account set up and by prior agreement with TBFS)

T. Bailey Fund Services Limited is authorised and regulated by the Financial Conduct Authority (No. 190293).

Platform Partners



Important information:

This information should not be construed as an invitation, offer or recommendation to buy or sell investments, shares or securities or to form the basis of a contract to be relied on in any way and is by way of information only. Taxation levels, benefits and reliefs may all vary depending on individual circumstances and are subject to change. The historic yield reflects distribution payments declared by the fund over the previous year as a percentage of its share price. This document represents the views of Saracen Fund Managers Limited at the time of writing. Subscriptions will only be received and shares issued on the basis of the current Prospectus, Key Investor Information Document (KIID) and Supplementary Information Document (SID). These are available, in English, together with information on how to buy and sell shares, on-line at: www.tbaileyfs.co.uk.

Risk factors you should consider before investing:

The value of investments and the income from them may go down as well as up and you may get back less than the amount invested. **Past performance is not a guide to future performance.** A full list of the risks applicable to this Fund can be found in the Prospectus. All fund performance figures calculated on a single price basis. This Fund may not be appropriate for investors who plan to withdraw their money in the short-term (within 5 years). The Fund should be viewed as a medium to long-term investment only.

Investment Manager:

Saracen Fund Managers Ltd, 19 Rutland Square, Edinburgh, EH1 2BB. Tel: 0131 202 9100 and on-line at www.saracenfundmanagers.com. Saracen Fund Managers Limited is authorised and regulated by the Financial Conduct Authority. Registered in Scotland No. 180545.

Issued by Saracen Fund Managers Limited. Please note that Saracen Fund Managers Limited do not provide financial advice. If you have any doubt whether the TB Saracen Global Income and Growth Fund is suitable for you and you wish to receive advice you should contact your Financial Adviser.

Regulatory Status:

FCA Recognised: Yes
Scheme Type: OEIC (UCITS)

Issue date – 31st January 2019